http://epogen.legalview.com/msn/ 2012-02-23 http://epogen.legalview.com/msn/after-market-movers-for-apr-20-scss-ffiv-slm-yum-qcom-cmg-gild-amgn/1330901/ 2012-02-23 http://epogen.legalview.com/msn/amgen-1q-profit-eases-but-adjusted-eps-tops-views/1330900/ 2012-02-23 http://epogen.legalview.com/msn/amgen-profit-falls-4-percent-as-costs-rise/1330899/ 2012-02-23 http://epogen.legalview.com/msn/amgen-1q-profit-falls-36-as-costs-rise/1330898/ 2012-02-23 http://epogen.legalview.com/msn/amgen-1q-profit-falls-4-percent-on-higher-costs/1330897/ 2012-02-23 http://epogen.legalview.com/msn/amgens-first-quarter-profit-falls-36-on-declining-sales-of-anemia-drug/1330896/ 2012-02-23 http://epogen.legalview.com/msn/smoke-free-laws-moving-ahead-in-us/1330895/ 2012-02-23 http://epogen.legalview.com/msn/no-party-for-health-care-investors-one-year-later/1314961/ 2012-02-23 http://epogen.legalview.com/msn/the-takyrovidnyj-factor-of-communications-high-lights/1314960/ 2012-02-23 http://epogen.legalview.com/msn/pharmaceutical-companies-eye-biosimilars-opportunities/1314959/ 2012-02-23 http://epogen.legalview.com/msn/medicare-wont-set-new-rules-on-anemia-drugs/1314958/ 2012-02-23 http://epogen.legalview.com/msn/is-wall-street-right-about-these-stocks/1297520/ 2012-02-23 http://epogen.legalview.com/msn/the-next-big-move-for-the-smartest-biotech-investor/1297519/ 2012-02-23 http://epogen.legalview.com/msn/psa-screening-for-prostate-cancer-dips-in-large-us-health-network/1297518/ 2012-02-23 http://epogen.legalview.com/msn/mylan-faces-generic-industrys-future-video/1297517/ 2012-02-23 http://epogen.legalview.com/msn/entry-into-a-material-definitive-agreement/1268141/ 2012-02-23 http://epogen.legalview.com/msn/goldmans-bold-call-on-dialysis-bundling-sell-amgen-buy-davita/1268140/ 2012-02-23 http://epogen.legalview.com/msn/amgen-pipeline-products-performance-and-potential-new-market-report-an/1259848/ 2012-02-23 http://epogen.legalview.com/msn/amgen-holder-invesco-says-actelion-not-compelling/1259847/ 2012-02-23 http://epogen.legalview.com/msn/name-investors-not-keen-on-amgen-acquisition-of-actelion/1259846/ 2012-02-23 http://epogen.legalview.com/msn/amgen-earnings-conference-call-q4-2010/1259845/ 2012-02-23 http://epogen.legalview.com/msn/research-and-markets-amgen-pipeline-products-performance-and-potential/1259844/ 2012-02-23 http://epogen.legalview.com/msn/health-news-anemia-drugs-hivaids-study/1248949/ 2012-02-23 http://epogen.legalview.com/msn/update-2-us-fda-seeks-advice-on-amgen-jj-anemia-drugs/1248948/ 2012-02-23 http://epogen.legalview.com/msn/a-best-case-scenario-for-amgens-anemia-drugs/1248947/ 2012-02-23 http://epogen.legalview.com/msn/fda-panel-backs-anemia-drugs-for-kidney-disease/1248946/ 2012-02-23 http://epogen.legalview.com/msn/amgn-pwrmob-protob-3-biotechnology-companies-discovering-cures-one-cel/1238321/ 2012-02-23 http://epogen.legalview.com/msn/company-funded-drug-studies-find-harm-less-often/1238320/ 2012-02-23 http://epogen.legalview.com/msn/keryx-remains-a-focused-well-funded-bio-pharma-play/1238319/ 2012-02-23 http://epogen.legalview.com/msn/deutsche-bank-starts-amgen-amgn-at-hold/1229154/ 2012-02-23 http://epogen.legalview.com/msn/biosimilar-development-progresses-without-fda-guidelines/1229153/ 2012-02-23 http://epogen.legalview.com/msn/why-dialysis-remains-an-attractive-business/1229152/ 2012-02-23 http://epogen.legalview.com/msn/hospira-initiates-phase-i-anemia-trial-in-renal-patients/1220829/ 2012-02-23 http://epogen.legalview.com/msn/affymax-lives-to-fight-another-day-in-bid-to-challenge-amgens-monopoly/1220828/ 2012-02-23 http://epogen.legalview.com/msn/hospira-to-test-generic-anemia-drug/1220827/ 2012-02-23 http://epogen.legalview.com/msn/hospira-initiates-us-phase-i-clinical-trial-of-biosimilar-erythropoiet/1220826/ 2012-02-23 http://epogen.legalview.com/msn/medicare-rules-threaten-epogen-with-38-drop/1220825/ 2012-02-23 http://epogen.legalview.com/msn/hospira-plans-big-study-for-new-epogen-biosimilar/1220824/ 2012-02-23 http://epogen.legalview.com/msn/medicare-cut-in-dialysis-fees-may-slash-amgen-sales-of-anemia-drug-epo/1220823/ 2012-02-23 http://epogen.legalview.com/msn/shakomendeds-wife-gets-lifeline/1212792/ 2012-02-23 http://epogen.legalview.com/msn/allocure-with-stem-cell-therapy-for-kidney-failure-arrives-in-new-engl/1212791/ 2012-02-23 http://epogen.legalview.com/msn/grand-jury-subpoenas-issued-for-armstrong-doping-investigation/1212790/ 2012-02-23 http://epogen.legalview.com/msn/correction-pfizer-drug-failure-story/1212789/ 2012-02-23 http://epogen.legalview.com/msn/eli-lilly-2q-sales-for-key-drugs-at-a-glance/1212788/ 2012-02-23 http://epogen.legalview.com/msn/biovex-appoints-steven-kelly-as-chief-commercial-officer/1203802/ 2012-02-23 http://epogen.legalview.com/msn/biovex-names-innoviveas-kelly-as-chief-commercial-officer/1203801/ 2012-02-23 http://epogen.legalview.com/msn/clinical-trial-results-affect-several-stocks/1203800/ 2012-02-23 http://epogen.legalview.com/msn/fda-weighs-benefits-risks-of-novartis-ms-pill/1193544/ 2012-02-23 http://epogen.legalview.com/msn/summary-box-novartis-multiple-sclerosis-drug/1193543/ 2012-02-23 http://epogen.legalview.com/msn/doctors-office-injection-for-osteoporosis-gets-ok/1193542/ 2012-02-23 http://epogen.legalview.com/msn/genzyme-nominates-dennis-fenton-for-election-to-its-board/1193541/ 2012-02-23 http://epogen.legalview.com/msn/amgen-drug-becomes-first-biologic-for-primary-care-update3/1193540/ 2012-02-23 http://epogen.legalview.com/msn/dennis-fenton-nominated-for-election-to-genzymes-board-of-directors/1193539/ 2012-02-23 http://epogen.legalview.com/msn/this-weeks-5-smartest-stock-moves/1193538/ 2012-02-23 http://epogen.legalview.com/msn/police-seek-cremains-stealing-wackjob/1184122/ 2012-02-23 http://epogen.legalview.com/msn/mercks-ditching-of-aranesp-biosimilar-highlights-follow-on-biologics/1184121/ 2012-02-23 http://epogen.legalview.com/msn/10-stocks-to-watch-in-the-next-week/1184120/ 2012-02-23 http://epogen.legalview.com/msn/taxing-the-sick-how-fees-in-health-care-reform-hurt-patients/1174471/ 2012-02-23 http://epogen.legalview.com/msn/global-anemia-drugs-market-to-exceed-88-billion-by/1165948/ 2012-02-23 http://epogen.legalview.com/msn/united-states-pharmaceuticals-and-healthcare-report-q2/1158858/ 2012-02-23 http://epogen.legalview.com/msn/are-you-buying-illegal-drugs/1158857/ 2012-02-23 http://epogen.legalview.com/msn/davita-inc-under-investigation-for-dva-investors/1150460/ 2012-02-23 http://epogen.legalview.com/msn/sp-amgen-inc-proposed-1-billion-senior-unsecured/1150459/ 2012-02-23 http://epogen.legalview.com/msn/piper-jaffray-initiates-coverage-on-affymax-affy-with/1150458/ 2012-02-23 http://epogen.legalview.com/msn/a-cautious-look-at-amgens-denosumab/1150457/ 2012-02-23 http://epogen.legalview.com/msn/35-comments/1142116/ 2012-02-23 http://epogen.legalview.com/msn/who-hit-me/1142115/ 2012-02-23 http://epogen.legalview.com/msn/profiteers-peddling-flu-vaccine/1133552/ 2012-02-23 http://epogen.legalview.com/msn/anemia-drug-may-raise-stroke-risk-in-kidney-patients/1128680/ 2012-02-23 http://epogen.legalview.com/msn/corrected-affymax-hematide-comparable-to-epogen-in-trial/1128679/ 2012-02-23 http://epogen.legalview.com/msn/mobile-dialysis-improves-patients-health-survival-rates/1123225/ 2012-02-23 http://epogen.legalview.com/msn/sunlight-researchtm-releases-its-amgen-epo-patents-report/1123224/ 2012-02-23 http://epogen.legalview.com/msn/roche-drops-defense-against-amgen-at-itc/1123223/ 2012-02-23 http://epogen.legalview.com/msn/sunlight-researchtm-releases-its-amgen-epo-patents-report/1118693/ 2012-02-23 http://epogen.legalview.com/msn/update-1-court-upholds-ban-on-us-sales-of-roche-drug/1118692/ 2012-02-23 http://epogen.legalview.com/msn/appeals-court-sides-with-amgen-in-patent-dispute/1118691/ 2012-02-23 http://epogen.legalview.com/msn/us-seeks-bundled-payment-for-kidney-dialysis/1118690/ 2012-02-23 http://epogen.legalview.com/msn/sports-biz-video-gallery/1118689/ 2012-02-23 http://epogen.legalview.com/msn/this-weeks-5-smartest-stock-moves/1113866/ 2012-02-23 http://epogen.legalview.com/msn/negative-for-prohibited-blood-doping-agents/1113865/ 2012-02-23 http://epogen.legalview.com/msn/pharmas-market-video/1113864/ 2012-02-23 http://epogen.legalview.com/msn/7-reasons-not-to-worry-this-week/1113863/ 2012-02-23 http://epogen.legalview.com/msn/update-2-amgen-trial-finds-no-heart-benefit-with-aranesp/1113862/ 2012-02-23 http://epogen.legalview.com/msn/sports-biz-video-gallery/1113861/ 2012-02-23 http://epogen.legalview.com/msn/amgen-aranesp-doesnt-show-significant-bad-effects-in-study/1113860/ 2012-02-23